A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis. — CFSMEATLAS
A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Brenu, Ekua W, Broadley, Simon, Nguyen, Thao et al. · Journal of immunology research · 2016 · DOI
Quick Summary
This study looked at specific immune cells called CD8+ T cells in people with ME/CFS and compared them to people with multiple sclerosis and healthy controls. Researchers found that ME/CFS patients had lower levels of certain proteins on their CD8+ T cells that help these immune cells function properly. These findings suggest that ME/CFS may involve problems with how immune cells are working, similar to but different from what happens in multiple sclerosis.
Why It Matters
Understanding differences in CD8+ T cell function between ME/CFS and other conditions like MS may help explain the unique pathophysiology of ME/CFS and could eventually guide development of targeted immune therapies. This study provides early evidence that ME/CFS involves measurable immune dysfunction, supporting the biological basis of the condition and potentially helping to differentiate it from other diseases.
Observed Findings
CD127 expression was significantly decreased on all CD8+ T cell subsets in ME/CFS patients compared to nonfatigued controls.
PSGL-1 expression was significantly reduced on CD8+ T cells in ME/CFS patients compared to controls.
MS patients showed increased expression of BTLA, CD127, and CD49/CD29 on CD8+ T cell subsets, a pattern distinct from ME/CFS patients.
CD8+ T cells from ME/CFS and MS patients demonstrated different immune receptor expression profiles despite both being systemic conditions.
The study included 23 ME/CFS patients, 11 untreated MS patients, and 30 healthy controls.
Inferred Conclusions
ME/CFS and MS are associated with significant deficits in CD8+ T cell surface receptor and adhesion molecule expression, but the patterns differ between conditions.
Reduced CD127 and PSGL-1 on CD8+ T cells may contribute to immune dysfunction in ME/CFS pathogenesis.
The distinct CD8+ T cell profiles between ME/CFS and MS suggest different underlying immune mechanisms despite some phenotypic similarities.
Remaining Questions
What functional consequences do these CD8+ T cell abnormalities have for immune responses in ME/CFS patients?
Do these immune markers correlate with ME/CFS symptom severity or disease duration?
What This Study Does Not Prove
This small preliminary study does not prove that CD8+ T cell abnormalities cause ME/CFS, only that they are associated with it. It cannot explain why these immune changes occur or what role they play in ME/CFS symptoms. The findings require confirmation in larger, well-powered studies before clinical significance can be established.